FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
CAMBRIDGE, Mass. and EXTON, Pa., March 03, 2016 -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Executive Officer, Vincent Milano will present at the Cowen and Company 36th Annual Healthcare Conference on Monday, March 7, 2016 at 4:00 p.m. Eastern Time at the Marriott Copley Place in Boston.
The company is also announcing that Louis Arcudi, Idera’s Chief Financial Officer will present at the 28th Annual Roth Conference on Monday, March 14, 2016 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time). The conference is being held at the Ritz Carlton in Dana Point, CA.
Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. Archived versions will also be available on the Company’s website after the event for 90 days. A copy of Idera’s slide presentation will be posted to the Investor’s section of the corporate website on Monday, March 7, 2016.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) [email protected]
